Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate- resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil (UTN U1111-1206- 1132). This evidence concerns the gene FOLH1 and Familial prostate cancer.